Mrs. Carol Anne Jackson, OTA Physical Medicine & Rehabilitation - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 10710 Se 160th Court Rd, Ocklawaha, FL 32179 Phone: 352-750-6619 |
News Archive
Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).
When someone is admitted to hospital, doctors often have to treat them with antibiotics while awaiting the results of time-consuming tests, with even the most advanced microbiology culture taking several days to get results.
While many college football fans are focused on this week's marquee matchup between the Georgia Bulldogs and the Clemson Tigers, researchers from the two institutions are working together off the playing field to develop low-cost technology that can detect cancer.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.
› Verified 2 days ago